MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
269.98
+0.60
+0.22%
After Hours: 269.98 0 0.00% 16:18 04/26 EDT
OPEN
265.72
PREV CLOSE
269.38
HIGH
271.68
LOW
265.72
VOLUME
2.44M
TURNOVER
0
52 WEEK HIGH
329.72
52 WEEK LOW
206.75
MARKET CAP
144.81B
P/E (TTM)
21.62
1D
5D
1M
3M
1Y
5Y
Diving Into Deciphera Pharmaceuticals
Shares of Deciphera Pharmaceuticals, Inc. Have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT. Vimsel tinib is expected to make significant progress in the TGCT indication. The company's switch-control kinase inhibitor platform aims to produce compounds that target specific regions of kinases.
Seeking Alpha · 3h ago
Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day
Seeking Alpha's Catalyst Watch includes a look at next week's key events. The Russell indices' ranking day will be used for the reconstitution of the firm's U.S. Indexes on April 26, 2024. Shares of Tesla will update monthly deliveries of electric vehicles in China. Apple's earnings and Viking's IPO are the focus of the week.
Seeking Alpha · 4h ago
Validea Detailed Fundamental Analysis - AMGN
NASDAQ · 10h ago
Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza
There are currently no approved treatments in Europe for thyroid eye disease. Tepezza is the bestselling drug of Horizon Therapeutics, which Amgen acquired last year. Amgen plans to seek European regulatory approval for the sale of its blockbuster treatment for the disease. The U.S. Food and Drug Administration approved the drug in 2020.
Dow Jones · 10h ago
Amgen Seeks EMA Approval For Teprotumumab In Moderate To Severe Thyroid Eye Disease
Amgen to submit a marketing authorization application to the European Medicines Agency for teprotumumab for the treatment of moderate to severe Thyroid Eye Disease in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease. If approved, it would be the first and only medicine approved for TED in the European Union.
Benzinga · 10h ago
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
Reuters · 10h ago
EMA SAYS CHMP ADOPTED POSITIVE OPINIONS FOR WEZENLA FOR TREATMENT OF PLAQUE PSORIASIS, INCLUDING PAEDIATRIC PLAQUE PSORIASIS, PSORIATIC ARTHRITIS
Reuters · 12h ago
O'Keefe Stevens Advisory Q1 2024 Investor Letter
Seeking Alpha · 14h ago
More
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.